These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19288004)

  • 1. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis.
    Orditura M; De Vita F; Galizia G; Lieto E; Vecchione L; Vitiello F; Martinelli E; Ciardiello F
    Oncol Rep; 2009 Apr; 21(4):1023-8. PubMed ID: 19288004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis.
    Su X; Lacouture ME; Jia Y; Wu S
    Oncology; 2009; 77(2):124-33. PubMed ID: 19622903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Crit Rev Oncol Hematol; 2015 Feb; 93(2):127-35. PubMed ID: 25139841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.
    Nardone B; Nicholson K; Newman M; Guitart J; Gerami P; Talarico N; Yang XJ; Rademaker A; West DP; Lacouture ME
    Clin Cancer Res; 2010 Sep; 16(17):4452-60. PubMed ID: 20732960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147.
    Jatoi A; Green EM; Rowland KM; Sargent DJ; Alberts SR
    Oncology; 2009; 77(2):120-3. PubMed ID: 19622902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
    Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
    Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skin rash during cetuximab treatment in advanced colorectal cancer: is age a clinical predictor?
    Giuliani J; Marzola M
    J Gastrointest Cancer; 2013 Jun; 44(2):241-5. PubMed ID: 23532731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.
    Gatzemeier U; von Pawel J; Vynnychenko I; Zatloukal P; de Marinis F; Eberhardt WE; Paz-Ares L; Schumacher KM; Goddemeier T; O'Byrne KJ; Pirker R
    Lancet Oncol; 2011 Jan; 12(1):30-7. PubMed ID: 21169060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
    Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
    Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).
    Jatoi A; Rowland K; Sloan JA; Gross HM; Fishkin PA; Kahanic SP; Novotny PJ; Schaefer PL; Johnson DB; Tschetter LK; Loprinzi CL
    Cancer; 2008 Aug; 113(4):847-53. PubMed ID: 18543329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer.
    Waris W; Naik S; Idrees I; Taha H; Camosino L; Mehrishi A; Saif MW
    Cutan Ocul Toxicol; 2009; 28(1):41-4. PubMed ID: 19514925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cetuximab in combination with chemotherapy for patients with gastrointestinal cancer].
    Zhang XT; Shen L; Zhang XD; Li J; Zhang ZT
    Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):385-8. PubMed ID: 18953842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials.
    Petrelli F; Borgonovo K; Barni S
    Target Oncol; 2013 Sep; 8(3):173-181. PubMed ID: 23321777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibody-induced papulopustular rash: Clinical course, communication to health-care professionals and reactive measures as reported by patients.
    Cignola S; Gonella S; Alessandra B; Palese A
    Eur J Oncol Nurs; 2016 Feb; 20():133-9. PubMed ID: 26187661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4).
    Jatoi A; Thrower A; Sloan JA; Flynn PJ; Wentworth-Hartung NL; Dakhil SR; Mattar BI; Nikcevich DA; Novotny P; Sekulic A; Loprinzi CL
    Oncologist; 2010; 15(9):1016-22. PubMed ID: 20798191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis.
    Wei F; Shin D; Cai X
    Int J Clin Oncol; 2018 Jun; 23(3):443-451. PubMed ID: 29289981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group.
    Stintzing S; Kapaun C; Laubender RP; Jung A; Neumann J; Modest DP; Giessen C; Moosmann N; Wollenberg A; Kirchner T; Heinemann V
    Int J Cancer; 2013 Jan; 132(1):236-45. PubMed ID: 22644776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy.
    Pinto C; Barone CA; Girolomoni G; Russi EG; Merlano MC; Ferrari D; Maiello E; ;
    Oncologist; 2011; 16(2):228-38. PubMed ID: 21273511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between EGFR gene polymorphisms, skin rash and response to anti-EGFR therapy in metastatic colorectal cancer patients.
    Jaka A; Gutiérrez-Rivera A; Ormaechea N; Blanco J; La Casta A; Sarasqueta C; Izeta A; Tuneu A
    Exp Dermatol; 2014 Oct; 23(10):751-3. PubMed ID: 25039761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.